The deletion of ERO1α or inhibition with a small-molecule inhibitor B12-5 (IC50 = 7.9 μM) results in reduced infarct volume and improved neurological outcomes in ischemic stroke models, indicating that targeting ERO1α may offer potential benefits in stroke treatment. This evidence concerns the gene ERO1A and ischemic stroke.